Cargando…

An open-label pilot study with high-dose thiamine in Parkinson's disease

Detalles Bibliográficos
Autores principales:	Costantini, Antonio, Fancellu, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828997/ https://www.ncbi.nlm.nih.gov/pubmed/27127471 http://dx.doi.org/10.4103/1673-5374.179047

Ejemplares similares

Can long-term thiamine treatment improve the clinical outcomes of myotonic dystrophy type 1?
por: Costantini, Antonio, et al.
Publicado: (2016)

Thiamine and diabetes: back to the future?
por: Beltramo, Elena, et al.
Publicado: (2021)

Oral High-Dose Thiamine Improves the Symptoms of Chronic Cluster Headache
por: Antonio, Costantini, et al.
Publicado: (2018)

Supplemental thiamine as a practical, potential way to prevent Alzheimer's disease from commencing
por: Fessel, Jeffrey
Publicado: (2021)

High-Dose Thiamine Supplementation in Older Patients With Heart Failure: A Pilot Randomized Controlled Crossover Trial (THIAMINE-HF)
por: Wong, Eric K.C., et al.
Publicado: (2022)

Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson’s Disease: Rationale, Design and Methods of the EXosomes in PArkiNson Disease (EXPAND) Study
por: Picca, Anna, et al.
Publicado: (2019)

Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording
por: Calandra-Buonaura, Giovanna, et al.
Publicado: (2016)

Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open‐Label Pilot Study
por: Khlebtovsky, Alexander, et al.
Publicado: (2019)

Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects
por: Smithline, Howard A, et al.
Publicado: (2012)

Wernicke's encephalopathy in a child with high dose thiamine therapy
por: Park, So Won, et al.
Publicado: (2014)

High-dose thiamine strategy in Wernicke–Korsakoff syndrome and related thiamine deficiency conditions associated with alcohol use disorder
por: Praharaj, Samir Kumar, et al.
Publicado: (2021)

Cell Therapies for Parkinson's Disease
por: Irion, Stefan
Publicado: (2019)

Mitochondria in the context of Parkinson's disease
por: Villacé, Patricia, et al.
Publicado: (2017)

Falling upward with Parkinson’s disease
por: Buetow, Stephen A., et al.
Publicado: (2017)

A single-arm open-label pilot study of brief mindfulness meditation to control impulsivity in Parkinson’s disease
por: Koh, Jinsoo, et al.
Publicado: (2022)

The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study
por: Suzuki, Keisuke, et al.
Publicado: (2022)

Efficacy of Wearable Device Gait Training on Parkinson's Disease: A Randomized Controlled Open-label Pilot Study
por: Kawashima, Noriko, et al.
Publicado: (2022)

Non-pharmacological interventions for Parkinson's disease mild cognitive impairment: future directions for research
por: Cammisuli, Davide Maria, et al.
Publicado: (2020)

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
por: Sulzer, David, et al.
Publicado: (2020)

Real world studies are essential for drug therapy in Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Using multi-organ culture systems to study Parkinson’s disease
por: Reiner, Orly, et al.
Publicado: (2020)

Genetic Analysis of Pathways to Parkinson Disease
por: Hardy, John
Publicado: (2010)

Parkinson’s disease-associated melanin steal
por: Hinz, Marty, et al.
Publicado: (2014)

Parkinson’s disease: carbidopa, nausea, and dyskinesia
por: Hinz, Marty, et al.
Publicado: (2014)

Efficacy of cognitive rehabilitation in Parkinson's disease
por: Díez-Cirarda, María, et al.
Publicado: (2018)

The paradigm of protein acetylation in Parkinson’s disease
por: Yakhine-Diop, Sokhna M.S., et al.
Publicado: (2019)

The role of viruses in the pathogenesis of Parkinson’s disease
por: Baizabal-Carvallo, José Fidel, et al.
Publicado: (2020)

Using gait robotics to improve symptoms of Parkinson’s disease: an open-label, pilot randomized controlled trial
por: GRYFE, Pearl, et al.
Publicado: (2022)

Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view
por: Brugger, Florian, et al.
Publicado: (2015)

Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
por: Can, Adem T., et al.
Publicado: (2021)

The inherent high vulnerability of dopaminergic neurons toward mitochondrial toxins may contribute to the etiology of Parkinson's disease
por: Wimalasena, Kandatege
Publicado: (2016)

Brain repair for Parkinson’s disease: is the answer in the matrix?
por: Moriarty, Niamh, et al.
Publicado: (2018)

Potential role of biofeedback therapy for Parkinson’s disease
por: Kotani, Naoya, et al.
Publicado: (2021)

The second brain in Parkinson’s disease: fact or fantasy?
por: Yemula, Nehal, et al.
Publicado: (2022)

Redefining the hypotheses driving Parkinson’s diseases research
por: Farrow, Sophie L., et al.
Publicado: (2022)

Cell replacement for Parkinson’s disease: advances and challenges
por: Xiao, Bin, et al.
Publicado: (2023)

Wrapping up the role of pericytes in Parkinson’s disease
por: Stevenson, Taylor John, et al.
Publicado: (2023)

Comparative efficacy of surgical approaches to disease modification in Parkinson disease
por: Rahimpour, Shervin, et al.
Publicado: (2022)

Thiamine Diphosphate in Whole Blood, Thiamine and Thiamine Monophosphate in Breast-Milk in a Refugee Population
por: Stuetz, Wolfgang, et al.
Publicado: (2012)

Amorphization of Thiamine Mononitrate: A Study of Crystallization Inhibition and Chemical Stability of Thiamine in Thiamine Mononitrate Amorphous Solid Dispersions
por: Arioglu-Tuncil, Seda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1nmrqt8un3magjl1nqj6ntu3ns